Oramed is a biotechnology company focused on the commercial development of proprietrary oral delivery solutation. Currently, Oramed's leading product is the treatment of diabetes via an oral insulin capsule.
Oramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin Capsule Tue, 14 Nov 2017 13:00:00 +0000 "Data from our directed preclinical NASH studies and clinical studies of ORMD-0801 in diabetics has revealed, through exploratory endpoints, that our oral insulin capsule has the ability to reduce inflammation of the liver. Incidence of NASH is rapidly increasing, similar to the rates of increase in diabetes. We look forward to exploring ORMD-0801 as a potential treatment for NASH," stated Oramed CEO, Nadav Kidron.
Oramed Granted Broad Composition of Matter Patent in Europe for Oral Proteins Tue, 31 Oct 2017 12:35:00 +0000 JERUSALEM, Oct. 31, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the European Patent Office has issued to Oramed a notice of intent to grant a patent for broader claims for its invention titled, 'Methods and Compositions for Oral Administration of Proteins'. The patent covers Oramed's drugs including its oral insulin capsule ORMD-0801 which is currently in clinical development for type 1 and type 2 diabetes, as well as ORMD-0901, an oral GLP-1 analog capsule. Oramed's invention is designed to prevent the breakdown of protein-based drugs in the gastrointestinal track and promotes its crossing the small intestine.
Oramed to Present at the Diabetes Technology Meeting Tue, 24 Oct 2017 13:25:00 +0000 JERUSALEM , October 24, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) ( http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...
Oramed to Present at the Disruptive Growth Showcase Conference Mon, 25 Sep 2017 12:55:00 +0000 JERUSALEM , Sept. 25, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, ...
Oramed (ORMP): Successful Meeting with FDA for Oral Insulin Tue, 05 Sep 2017 13:00:00 +0000 By Grant Zeng, CFA NASDAQ:ORMP The FDA Meeting Earlier today (Sept. 5, 2017), Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced that it has successfully concluded a meeting with the US FDA regarding ...
Oramed Announces Successful Meeting with FDA for Oral Insulin Tue, 05 Sep 2017 10:00:00 +0000 JERUSALEM, Sept. 5, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has successfully concluded its meeting with the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, the Company's novel oral insulin formulation. At the meeting, the FDA gave clear guidance that the regulatory pathway for submission of ORMD-0801, would be a Biologics License Application (BLA). Such a pathway would grant a full 12 years of marketing exclusivity for ORMD-0801 if approved. On top of this, an additional six months of exclusivity can be granted if the product also receives approval for use in pediatric patients. The FDA confirmed that the approach to nonclinical toxicology, CMC and qualification of excipients would be driven by their published guidance documents, consistent with the Company's expectations. They also made specific recommendations for clinical trials designed to provide pivotal data prior to registration.
Oramed to Present at the Rodman & Renshaw Global Investment Conference Tue, 29 Aug 2017 12:50:00 +0000 JERUSALEM , August 29, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) ( http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...
Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs Tue, 18 Jul 2017 12:50:00 +0000 JERUSALEM, July 18, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Simon Bruce MD to the newly created position of Vice President of Medical Affairs. "We are very pleased to welcome Dr. Bruce on board at this pivotal time for Oramed as we prepare for the initiation of a Phase III trial for our oral insulin capsule, ORMD-0801. Dr. Bruce will be tasked with leading all of our clinical development programs, with the specific near-term focus on bringing our oral insulin (ORMD-0801) through regulatory approval and into commercialization," stated Oramed CEO, Nadav Kidron.
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.
Accum/Dist: 0.86 (median winner: 1.53)
Instit. Ownership: 2% (median winner: 63%)
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.